Earlier this month, antitrust lawyers and enforcers from around the globe convened in Washington, D.C., for the annual ...

Whacking up tariffs might in theory help bring business back onshore. A bar chart showing US pharma imports Trump would therefore need drugmakers to upend a complex, expensive manufacturing system.

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

LONDON/NEW YORK, April 1 (Reuters) - Drugmakers are lobbying U.S. President Donald Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the charges and ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Merck KGaA, Pfizer and Sanofi were among more than 40 international business leaders who met with Xi in ...

Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. The main reason for this is that, somewhat unexpectedly, the Trump administration didn't impose tariffs ...